Hoffer and Osmond pioneer psychedelic therapy as a treatment for mental illness

Story: 1951 C.E.  |  Last updated: January 12, 1951

In the early 1950s C.E., a pair of researchers working in the psychiatric wards of Saskatchewan, Canada, began administering LSD to patients with alcoholism — and watching something remarkable happen. Abram Hoffer and Humphrey Osmond weren’t fringe figures. They were credentialed scientists asking a serious question: could a carefully guided psychedelic experience produce lasting psychological change? Their answer, drawn from dozens of clinical cases, was yes. It was the beginning of a field that would be buried, rediscovered, and is now reshaping psychiatry.

Key findings

• Psychedelic therapy: Hoffer and Osmond’s early 1950s C.E. trials at Weyburn Mental Hospital in Saskatchewan used LSD in structured therapeutic sessions to treat alcoholism, reporting significant abstinence rates that drew international attention.
• LSD research: Their work contributed to a decade of extraordinary scientific output — by the mid-1960s C.E., over 1,000 peer-reviewed clinical papers had been published detailing psychedelic compounds administered to approximately 40,000 patients across multiple countries.
• Humphrey Osmond’s legacy: Osmond coined the word “psychedelic” in 1957 C.E. in a correspondence with writer Aldous Huxley — a term meaning “mind-manifesting” that would define an entire era of research, counterculture, and eventual clinical revival.

A tradition older than the clinic

Hoffer and Osmond were entering a conversation that had been underway for thousands of years.

Indigenous peoples across the Americas, Africa, and Eurasia had long used plant-based psychedelics — peyote, psilocybin mushrooms, ayahuasca, ibogaine — in healing and ceremonial contexts. Shamans and medicine people understood that altered states of consciousness could facilitate psychological and spiritual transformation. These traditions weren’t primitive precursors to modern medicine. They were sophisticated, community-embedded therapeutic systems in their own right.

What Hoffer, Osmond, and their colleagues did was translate that ancient insight into the language of mid-20th-century psychiatry. Their clinical framework — prepare the patient, administer the substance in a supportive setting, then integrate the experience — closely mirrors ceremonial structures that Indigenous healers had refined over generations. That parallel is not a coincidence. It reflects something real about how the human mind processes difficulty and transformation.

What the 1950s research actually showed

Albert Hofmann had discovered LSD’s psychoactive properties in 1943 C.E. By 1949 C.E., Sandoz Laboratories was distributing it to researchers worldwide. The window that followed was one of the most productive — and most controversial — periods in the history of psychiatry.

Hoffer and Osmond’s Saskatchewan trials showed promise for alcoholism treatment. Timothy Leary’s experiments at Harvard explored whether psilocybin could reduce recidivism among prison inmates. Researchers at institutions across the U.S. and Europe tested psychedelics for anxiety in terminal illness, autism spectrum conditions in children, and treatment-resistant depression. Six international conferences were held. The science was serious, and the results were often striking.

Proponents believed psychedelics could catalyze breakthroughs in psychoanalytic processes — helping patients access emotional material that conventional talk therapy couldn’t reach. The idea was not that the drug healed. It was that the experience, properly guided, created conditions for healing.

How prohibition ended the first era

By the mid-1960s C.E., the political atmosphere had shifted decisively against psychedelic research. Concerns about unauthorized recreational use — particularly among the counterculture — led governments to impose severe restrictions. Sandoz halted LSD production in 1965 C.E. The U.S. Controlled Substances Act of 1970 placed LSD, psilocybin, and many related compounds in Schedule I — the most restrictive category, reserved for substances deemed to have no accepted medical use and high abuse potential.

Clinical trials stopped. Careers ended. A generation of research was effectively sealed off.

Senator Robert F. Kennedy, testifying at a 1966 C.E. congressional hearing, expressed what many in the scientific community felt: “Perhaps to some extent we have lost sight of the fact that [LSD] can be very, very helpful in our society if used properly.” A 1968 C.E. paper in the American Journal of Psychiatry documented how political and pharmaceutical pressures had systematically discredited legitimate research — canceling studies and labeling genuine scientists as charlatans.

Despite prohibition, psychedelic therapy didn’t disappear. Underground networks of licensed therapists and self-taught practitioners continued working through the 1970s and 1980s C.E., largely undocumented. The field survived in the shadows.

Lasting impact

The revival began quietly in the early 2000s C.E. Advances in neuroscience and brain imaging gave researchers new tools to understand what psychedelics actually do. Institutions including Imperial College London, Johns Hopkins, and NYU launched rigorous new trials. The results were striking enough that the U.S. Food and Drug Administration granted “breakthrough therapy” status to psilocybin for treatment-resistant depression and major depressive disorder, and to MDMA for post-traumatic stress disorder — a regulatory designation that accelerates review of unusually promising treatments.

Oregon became the first U.S. state to legalize supervised psilocybin therapy in 2020 C.E., with facilitator training programs now underway. The framework — prepare, administer, integrate — is almost identical to what Hoffer and Osmond pioneered in Saskatchewan seven decades earlier.

The downstream consequences of those early 1951 C.E. experiments extend beyond any single treatment. They proposed a fundamentally different model of psychiatric care: one that treats a single guided experience, rather than daily medication, as the vehicle for change. That model is now attracting serious scientific and institutional investment worldwide.

Blindspots and limits

The early trials, including Hoffer and Osmond’s, did not meet the methodological standards required of clinical research today — many lacked control groups, blinding, or rigorous outcome measurement. The current body of evidence, though promising, remains relatively small, and larger studies are still needed to establish safety and effectiveness across diverse populations.

Commercialization has introduced new tensions: venture capital investment, patent disputes, and concerns about cultural appropriation of Indigenous healing traditions have all become live debates in the field. Equitable access — ensuring that psychedelic therapy doesn’t become a treatment available only to the wealthy — remains an unresolved challenge. And the legal status of these substances in most countries means that many people who might benefit still cannot access them safely.

Read more

For more on this story, see: Wikipedia — Psychedelic therapy

For more from Good News for Humankind, see:

• Global suicide rates have fallen by 40% since 1995
• Alzheimer’s risk cut in half by drug in landmark prevention trial
• The Good News for Humankind archive on mental health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.